Intensity Therapeutics to Present Data on Safety, Tumor Regression and Immune Activation of INT230-6 at ASCO 2019
WESTPORT, Conn.--(BUSINESS WIRE)-- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that a poster highlighting the safety profile, tumor regression activity and immune activation of the company’s lead product candidate, INT230-6, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 to June 4, 2019 in Chicago.
Details of the poster presentation are as follows:
|
Title: Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation |
|
Abstract Number: 2602 |
|
Date/Time: Saturday, June 1, 2019, 8-11 a.m. CDT |
|
Poster Session: Developmental Immunotherapy and Tumor Immunobiology |
|
Presenter: Jacob Stephen Thomas, MD, Assistant Professor of Clinical Medicine, University of Southern California |
|
About INT230-6 |
INT230-6, Intensity’s lead product candidate designed for direct intratumoral injection, is comprised of two proven, potent anti-cancer agents and a penetration enhancer molecule that helps disperse the drugs throughout tumors and diffuse into cancer cells. INT230-6 is being evaluated in a Phase 1/2 clinical study (NCT03058289) in patients with various advanced solid tumors. In preclinical studies, INT230-6 eradicated tumors by a combination of direct tumor kill and recruitment of dendritic cells to the tumor micro-environment that induced anti-cancer T-cell activation. Treatment with INT230-6 in in vivo models of severe cancer resulted in substantial improvement in overall survival compared to standard therapies. Further, INT230-6 provided complete responder animals with long-term, durable protection from multiple re-inoculations of the initial cancer and resistance to other cancers. In mouse models, INT230-6 has shown strong synergy with checkpoint blockage, including anti-PD-1 and anti-CTLA4 antibodies. INT230-6 was discovered from Intensity’s DfuseRxSM platform.
About Intensity Therapeutics
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity’s product candidates have the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases. INT230-6, Intensity’s lead product candidate, is being evaluated in a Phase 1/2 clinical study in patients with various advanced solid tumors. For more information, please visit www.intensitytherapeutics.com and follow us on Twitter @IntensityInc.
Forward Looking Statements
This press release contains forward-looking statements regarding Intensity Therapeutics’ plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005181/en/
Investors:
Kerry Conlin
Stern
Investor Relations
212-698-8685
kerry.conlin@sternir.com
Media:
Claire LaCagnina
6 Degrees
PR
(315) 765-1462 clacagnina@6degreespr.com
Source: Intensity Therapeutics, Inc.
Released May 16, 2019